特斯拉1月在中國銷量環比增18.38%
乘聯會發布的數據顯示,特斯拉(TSLA.US)於2023年1月在中國交付了26843輛汽車,比2021年12月的41926輛下降了35.98%,但同比增長了38.75%。特斯拉1月份在中國銷售了66051輛汽車,其中出口了39208輛。包括出口在內,1月份銷量環比增長18.38%,同比增長10.37%。
今年1月,中國新能源汽車零售量爲33.2萬輛,這意味着特斯拉在中國新能源汽車市場的份額爲8.09%,高於2022年12月的6.55%。
1 月初,該公司大幅降低了其在中國的全系 Model 3 和 Model Y 系列產品的價格。一月份的銷售數字反映了降價後的銷售業績。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.